- Research indicates that anti-inflammatory medications have the power to prevent the onset and control the symptoms of Alzheimer’s disease
- The link between inflammatory processes and Alzheimer’s has long been established; companies like INmune Bio are working to further the research and develop safe and effective drugs based on disrupting this mechanism
- INmune Bio has received a $1 million grant from the Alzheimer’s Association to bring its lead drug candidate, XPro1595, to the clinical testing stage
Could tumor necrosis factor-alpha (TNF-α) inhibition be the next big thing in the world of Alzheimer’s disease (AD) treatment? A detailed Washington Post report focuses on research carried out by a Pfizer Inc. (NYSE: PFE) team (http://nnw.fm/3R9va). According to the researchers, one of the company’s rheumatoid arthritis anti-inflammatory drugs appeared to reduce the risk of Alzheimer’s disease development by as much as 64 percent.
Pfizer researchers went through thousands of insurance claims in 2015, reaching the conclusion that the rheumatoid arthritis pharmaceutical had such an effect on AD. Carrying out a clinical trial to prove the findings, however, would have been an expensive endeavor in this case, with uncertain results, causing Pfizer to hold off.
A presentation prepared for review by an internal Pfizer committee in February 2018 noted that the drug (Enbrel) could “potentially safely prevent, treat, and slow progression of Alzheimer’s disease.” This suggests that the right approach to TNF-α inhibition medication has promise. TNF is an inflammatory cytokine that plays an important role in both inflammation and the body’s immune response. Soluble TNF (sTNF) is found circulating in the blood stream, and it has been linked to inflammatory processes, infections and even cancer.
Some members of the scientific community have pushed for further testing of the mechanism. According to these professionals, further examination of anti-inflammatory medications in the treatment of AD is warranted, because such investigations could highlight new mechanisms for the effective control and treatment of the condition.
Several pre-clinical studies have shown a connection between inflammation and Alzheimer’s disease pathology. In one of these trials, XPro1595 by INmune Bio Inc. (NASDAQ: INMB) prevented the accumulation of C-terminal amyloid beta protein. The conclusion reached was that the inhibition of soluble TNF signaling prevents pre-plaque amyloid-associated neuropathology, a risk factor implicated for its link to AD.
A link between TNF and AD has also been established in the clinic. Alzheimer’s disease patients have elevated serum levels of TNF. In addition, high TNF levels are seen to cause people who have mild cognitive impairment to progress to AD.
XPro1595 is an engineered protein that’s almost the same as sTNF. There are only two-point mutations in the coding sequence, and XPro1595 is formulated to keep sTNF from binding to TNFR – a mechanism that has been studied and shown to reduce pro-inflammatory signals.
A lot more work needs to be done on XPro1595, and, to advance the pursuit of medication for AD treatment, INmune Bio has secured a $1 million grant from the Alzheimer’s Association. With the funding, INmune Bio hopes to speed up pre-clinical research and help pharmaceutical developers move on to clinical testing.
Through the grant, INmune will carry out a phase 1 clinical trial in 18 patients suffering from mild to moderate AD. XPro1595 will be administered once per week over the course of three months. Biomarker inflammation will be assessed in the mid and end points of the trial.
Based in La Jolla, California, INmune Bio is a diversified, clinical-stage biotechnology company working to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. With its programs in oncology and neurodegenerative disease, the company offers significant investment opportunities with a considerable ROI.
For more information, visit the company’s website at www.INmuneBio.com
NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com